Vyleesi is the trade name for bremelanotide, a well-known peptide that was first studied as a possible tanning product. It activates melanocortin receptors and has been shown to help restore a natural sexual desire in women and men for many years. Recently it was FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD is a common, treatable medical condition characterized by ongoing low sexual desire that women find frustrating.
The new approval of this peptide means it will become more well-known for improving sexual desire in BOTH men and women.